-
Filter tips for safer pipetting and better accuracy
Biohit has launched new Safetyspace Filter Tips that have more space between the sample and the filter than conventional filter tips usually have.
-
Nya belägg för att boxning skadar hjärnan
Nervceller i hjärnan fortsätter att dö fortfarande två månader efter att boxare fått upprepade slag mot huvudet.
-
Handskbox med noggrann klimatkontroll
890-THC är en ny handskbox från Plas Labs som har ett noggrant kontrollerat klimat, touch-screen display och två metoder för avfuktning.
-
Hundar kan också få ALS
Forskare har identifierat en genmutation som orsakar amytrofisk lateralskleros hos flera hundraser. Samma gen ligger bakom samma sjukdom hos människor.
-
Success fee to Bioinvent and partner
The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
Eli Lilly writes biotech fine history
The American biotech company Eli Lilly will pay US 1.415 billion to resolve allegations of off-label promotion of a dementia drug.
-
Parnevik firm in Swiss osteoporosis deal
The golf legend Jesper Parnevik's drug delivery firm EffRx has signed a license agreement with Nycomed for a new drug against osteoporosis.
-
Collaboration brings next generation drugs
Wyeth and Santaris Pharma announce a new alliance to develop RNA-based medicines.
-
Medicult acquires embryo scanner
The Danish company Medicult signs an agreement with Novocellus to gain access to embryo selection technology.
-
Meda gets access to Asia
The biotech giant Meda has recently acquires world-wide rights to the cancer breakthrough pain drug Onsolis.
-
Pfizer buys Swiss vaccines
Pfizer executes commercial license agreements for novel human vaccines based on the Swiss company Cytos Biotechnology's Immunodrug technology.
-
Time to save for survival
The future is bright for the biotech industry. However, the companies need to cut costs immediately if they want to survive the rough economic times.
Få tillgång till allt innehåll på Life Science Sweden
Ingen bindningstid eller kortinformation krävs
Redan prenumerant? Logga in
Gäller endast personlig prenumeration.
Kontakta oss för en företagslösning.
BREAKING